Showing posts with label early detection. Show all posts
Showing posts with label early detection. Show all posts
Tuesday, June 15, 2010
Tuesday, May 25, 2010
New early screening for ovarian cancer 'promising': study
WASHINGTON — A new screening approach to detect early stage ovarian cancer in post-menopausal women has proven promising, researchers said of results to a study released Thursday.
"More than 70 percent of ovarian cancers are diagnosed when they have already grown to an advanced stage, so identifying a reliable screening test for early-stage disease would be like finding the Holy Grail," said the study's lead author Karen Lu, of the University of Texas' Anderson Cancer Center.
"This study is one step forward in that direction. If confirmed in larger studies, this approach could be a useful and relatively inexpensive tool for detecting ovarian cancer in its early, more curable stages," she said.
The results were presented by the American Society of Clinical Oncology (ASCO) ahead of its annual conference, to be held June 4-8 in Chicago.
The new method uses a mathematical model to assess trends in CA-125 blood test results -- a protein known to rise during the cancer's development -- and a patient's age. The model is then "followed by transvaginal ultrasound and referral to a gynecologic oncologist, if necessary," researchers said.
For up to eight years, the study followed 3,238 post-menopausal women aged 50 to 74 who had no significant family history of breast or ovarian cancer, and the accuracy of using the mathematical model followed by ultrasound was 99.7 percent, indicating few false-positives using the approach, researchers said.
A larger study involving more than 200,000 women is currently underway in Britain, with results expected by 2015.
Saturday, May 22, 2010
podcast: CA-125 Change Over Time Shows Promise as Screening Tool for Early Detection of Ovarian Cancer
CA-125 Change Over Time Shows Promise as Screening Tool for Early Detection of Ovarian Cancer
Blood test currently approved to find recurrence full of new possibility; invasive, high-grade disease uncovered at curable stageMD Anderson News Release 05/20/10
PLoS ONE: Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries
Note: full free access / technical
Background
MicroRNAs (miRNAs) are small regulatory RNAs that are implicated in cancer pathogenesis and have recently shown promise as blood-based biomarkers for cancer detection. Epithelial ovarian cancer is a deadly disease for which improved outcomes could be achieved by successful early detection and enhanced understanding of molecular pathogenesis that leads to improved therapies. A critical step toward these goals is to establish a comprehensive view of miRNAs expressed in epithelial ovarian cancer tissues as well as in normal ovarian surface epithelial cells.
Conclusions
This report expands the body of miRNAs known to be expressed in epithelial ovarian cancer and provides a useful resource for future studies of the role of miRNAs in the pathogenesis and early detection of ovarian cancer.
Discussion
The work reported here was motivated by the hypothesis that the entire repertoire of miRNAs expressed in ovarian cancer, including potentially tissue- and cancer-specific miRNAs, had not yet been elucidated.Thursday, April 29, 2010
Wednesday, April 28, 2010
abstract: New technologies for the detection of circulating tumour cells.
"The vast majority of cancer-related death is due to the metastatic spread of the primary tumour. Circulating tumour cells (CTC) are essential for establishing metastasis and their detection has long been considered as a possible tool to assess the aggressiveness of a given tumour and its potential of subsequent growth at distant organs.
Conventional markers are not reliable in detecting occult metastasis and, for example, fail to identify approximately 40% of cancer patients in need of more aggressive or better adjusted therapies. Recent studies in metastatic breast cancer have shown that CTC detection can be used as a marker for overall survival and assessment of the therapeutic response. The benefits of CTC detection in early breast cancer and other solid tumours need further validation.
Moreover, optimal CTC detection techniques are the subject of controversy as several lack reproducibility, sensitivity and/or specificity. Recent technical advances allow CTC detection and characterization at the single-cell level in the blood or in the bone marrow. Their reproducibility propels the use of CTC in cancer staging and real-time monitoring of systemic anticancer therapies in several large clinical trials.
CTC assays are being integrated in large clinical trials to establish their potential in the management of cancer patients and improve our understanding of metastasis biology. This review will focus on the techniques currently used, the technical advancements made, the limitations of CTC detection and future perspectives in this field."
Thursday, February 11, 2010
Friday, January 29, 2010
Thursday, January 28, 2010
Friday, January 22, 2010
Vermillion Emerges From Bankruptcy -- FREMONT, Calif., Jan. 22 /PRNewswire-FirstCall/ --
"This is a great day for all of our stakeholders as well as women who will benefit from OVA1,' said Gail Page, executive chair of Vermillion. 'We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease,' she added."
Thursday, December 31, 2009
full free access EDITORIAL: Designing Early Detection Programs for Ovarian Cancer -- JNCI
Subscribe to:
Posts
(
Atom
)
